Precision Medicine
Precision Medicine Group, often referred to as PMG, is a leading entity in the healthcare industry, headquartered in the United States. Founded in 2014, the company has rapidly established itself as a key player in the realms of clinical development, regulatory consulting, and commercialisation strategies, primarily serving the biopharmaceutical sector. With a focus on delivering tailored solutions, PMG offers a unique suite of services that includes biomarker development, patient recruitment, and real-world evidence generation. These offerings are designed to enhance the precision of medical treatments and improve patient outcomes. Recognised for its innovative approach, Precision Medicine Group has achieved significant milestones, positioning itself as a trusted partner for clients seeking to navigate the complexities of modern medicine. Its commitment to advancing personalised healthcare continues to set it apart in a competitive market.
DitchCarbon Score
How does Precision Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Precision Medicine's score of 3 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Precision Medicine's reported carbon emissions
Precision Medicine Group, headquartered in the United States, currently does not have available carbon emissions data for the most recent year. However, the company has made commitments towards reducing its carbon footprint. Precision Medicine is classified as "Committed" to near-term reduction targets, although specific numerical targets have not been disclosed. The company has not set a net-zero target and does not have a long-term reduction target established at this time. As part of the pharmaceuticals, biotechnology, and life sciences sector, Precision Medicine is expected to align with industry standards for climate action, focusing on reducing emissions across its operations. While specific emissions data is lacking, the commitment to reduction initiatives indicates a proactive approach to addressing climate change within the industry context.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Precision Medicine is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
